Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEN1047 first-in-human trial in advanced solid tumors
NL-OMON59756Phase 2Completed
- Sponsor
- Genmab
- Start
- Dec 2021
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of GEN1047 in Non-hematologic malignancy, breast cancer, endometrial cancer (EC) and 2 more (2 arms), sponsored by Genmab. Primary endpoints: Dose-limiting toxicities, Adverse events and safety laboratory parameters and 1 more. Started Dec 2021; status: completed.
02
Drugs
GEN1047
03
Conditions
Non-hematologic malignancybreast cancerendometrial cancer (EC)ovarian cancerPulmonary squamous cell carcinoma
Beyond the preview
Go deeper on NL-OMON59756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59756.